AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 86 filers reported holding AVADEL PHARMACEUTICALS PLC in Q1 2022. The put-call ratio across all filers is 0.45 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $988,800 | -37.5% | 96,000 | 0.0% | 0.50% | -32.1% |
| Q2 2023 | $1,582,080 | +79.9% | 96,000 | 0.0% | 0.74% | +80.0% |
| Q1 2023 | $879,360 | +27.9% | 96,000 | 0.0% | 0.41% | +29.4% |
| Q4 2022 | $687,360 | +43.2% | 96,000 | 0.0% | 0.32% | +26.4% |
| Q3 2022 | $480,000 | +105.1% | 96,000 | 0.0% | 0.25% | +129.4% |
| Q2 2022 | $234,000 | -43.8% | 96,000 | +57.4% | 0.11% | -37.7% |
| Q1 2022 | $416,000 | -15.4% | 61,000 | 0.0% | 0.18% | -13.4% |
| Q4 2021 | $492,000 | -17.6% | 61,000 | 0.0% | 0.20% | -24.9% |
| Q3 2021 | $597,000 | +45.6% | 61,000 | 0.0% | 0.27% | +48.6% |
| Q2 2021 | $410,000 | -25.6% | 61,000 | 0.0% | 0.18% | -28.2% |
| Q1 2021 | $551,000 | +35.4% | 61,000 | 0.0% | 0.25% | +22.9% |
| Q4 2020 | $407,000 | +32.6% | 61,000 | 0.0% | 0.20% | +24.2% |
| Q3 2020 | $307,000 | – | 61,000 | – | 0.16% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WEALTH EFFECTS LLC | 2,498,838 | $22,889,355 | 11.72% |
| Knoll Capital Management, LLC | 500,000 | $4,580,000 | 7.06% |
| GENDELL JEFFREY L | 5,301,914 | $48,565,532 | 4.55% |
| COWEN AND COMPANY, LLC | 3,732,778 | $34,192,246 | 4.02% |
| Tri Locum Partners LP | 1,327,097 | $12,156,209 | 3.70% |
| Samsara BioCapital, LLC | 1,409,409 | $12,910,186 | 2.67% |
| Altium Capital Management LP | 500,000 | $4,580,000 | 2.54% |
| Vivo Capital, LLC | 3,761,438 | $34,454,772 | 2.39% |
| RTW INVESTMENTS, LP | 5,741,939 | $52,596,161 | 1.10% |
| Knott David M Jr | 291,113 | $2,667 | 1.05% |